STOAF III SciTech invests in Stroke Alarm company Uman Sense

In an oversubscribed new share issue, the medtech company Uman Sense has raised SEK 6.3 million. Among the new co-owners are STOAF III SciTech, Gobia Enterprises, and Queen Invest. Uman Sense has developed and CE-marked the medical device Stroke Alarm, a medical device which is now being tested in a clinical trial on patients at a high risk for stroke.

Uman Sense’s medical device product Stroke Alarm is a wearable stroke detection system that consists of two bracelets with sensors and wireless communication with a smartphone. The purpose of Stroke Alarm is to provide early indication of suspected stroke so that the victim can access care in time for treatment. The product is intended for patients who are at high risk of stroke. Stroke Alarm addresses an important medical challenge and has already attracted great interest, including Region Skåne where a clinical trial has been initiated at several neurology clinics offering patients use of Stroke Alarm.

“One million brain cells are lost every minute during a stroke, so every minute saved from stroke onset to treatment increases the chance for the victim to survive and return to a good, productive life.”

“There are great medical, human and socio-economic benefits to be made if stroke patients come into care as early as possible. One million brain cells are lost every minute during a stroke, so every minute saved from stroke onset to treatment increases the chance for the victim to survive and return to a good, productive life,” according to Johan Wasselius, associate professor and consultant interventional neuroradiologist at Skåne University Hospital and one of the inventors of Stroke Alarm.

“Uman Sense is a very exciting company using advanced AI-based technology in an area where there is a large unmet clinical need. We believe that Stroke Alarm will significantly increase the chance to survive and get back to a healthy life after a stroke.  Uman Sense is great fit with our investment strategy, that focuses on deeptech and life science start-ups with a large global market potential who make an impact to create a better world,” says Magnus Eriksson, General Partner at STOAF III SciTech.

“It is great that we are able to bring in these strong and long-term partners. They will be able to contribute with their broad knowledge in building successful companies within life science,” says Cecilia Belfrage,” CEO of Uman Sense.

Owners preceding this investment series include Christer Fåhraeus’ Fårö Capital among others.

Uman Sense is a member of SmiLe Incubator, a business incubator in Medicon Village in Lund, Sweden that helps innovation companies in the field of Life Science to convert their ideas into reality.

More information is provided by: 

Cecilia Belfrage, CEO and co-founder Uman Sense, +46 (0)70-3377789, cecilia.belfrage@umansense.comwww.umansense.com

Magnus Eriksson, General Partner, STOAF III SciTech, +46 (0)733-400 464, magnus.eriksson@stoaf.se, www.stoaf.se/

About STOAF III Scitech
STOAF III SciTech is Stoaf’s third fund generation. SciTech primarily invests in Sweden but can also invest in the other Nordic countries. The focus is on early stage start-ups with advanced technologies (Deeptech) and Life Sciences that makes an impact.

STOAF III SciTech invests in Stroke Alarm company Uman Sense

oktober 21st, 2020|

In an oversubscribed new share issue, the medtech company Uman Sense has raised SEK 6.3 million. Among the new co-owners are STOAF III SciTech, Gobia Enterprises, and Queen Invest. Uman Sense has developed and CE-marked the medical device Stroke Alarm, a medical device which is now being tested in a clinical trial on patients at a high risk for stroke.

STOAF III SciTech invests in Developeration’s innovative surgical device

september 15th, 2020|

STOAF III SciTech och Almi Invest each invests 1.9 MSEK in Developeration AB, who has developed an innovative surgical instrument for treatment of hemmorhoids. The emission of 4.4 MSEK will be used for further product development and clinical trials. Hemorrhoids affect about 25 percent of the population over the age of 50 in the Western world. There are currently several different ways to treat hemorrhoids, but they carry a high risk of recurrence or complications, are expensive, take a long time, require access to the operating theater, are painful, or a combination of these.

STOAF II PORTFOLIO COMPANY ILYA PHARMA AWARDED €5.3M FROM EIC ACCELERATOR

juni 8th, 2020|

STOAF II PORTFOLIO COMPANY ILYA PHARMA AWARDED €5.3M FROM EIC ACCELERATOR TO FAST TRACK PHASE II STUDY OF FIRST-IN-CLASS ILP100 ADVANCE THERAPY FOR WOUND TREATMENT IN PEOPLE WITH DIABETES Ilya Pharma, a clinical stage biopharma company developing novel chemokine gene therapies with its ILP-technology platform, today announced that it has secured a total of Euros 5.3 million in funding from the European Innovation Council (EIC) Accelerator program of blended financing.

STOAF III SCITECH INVESTS IN VOC DIAGNOSTICS

maj 28th, 2020|

Stoaf III SciTech, Almi Invest and others invest 4,8 MSEK in VOC Diagnostics. It is part-financing of a further development and testing of its unique sensor-equipped instrument used for diagnosing ovarian cancer. VOC Diagnostics has recently employed Linda Spahiu as its CEO. The financing is to be used to complete the instrument for clinical use, clinical studies and CE certifcation.

SILICON VALLEY VC LEGEND CLIFFORD HIGGERSON INVESTS IN STOAF III SCITECH AND BECOMES ITS SENIOR ADVISOR

april 21st, 2020|

Cliff Higgerson, Palo Alto, CA, previous General Partner in several VC-funds in Silicon Valley invests in Stoaf III SciTech and accepts to become its Senior Advisor. "We are very happy to see the confidence of a Silicon Valley heavyweight such as Cliff shows for Stoaf by investing in our third fund" says the fund´s CEO and General Partner P A Wärn. "He will via his long and successful experience as General Partner in ComVentures and Vanguard Ventures contribute valuable competence to our GP team".